KYMR
Income statement / Annual
Last year (2023), Kymera Therapeutics, Inc.'s total revenue was $78.59 M,
an increase of 67.84% from the previous year.
In 2023, Kymera Therapeutics, Inc.'s net income was -$146.96 M.
See Kymera Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$78.59 M
|
$46.83 M
|
$72.83 M
|
$34.03 M
|
$2.93 M
|
$0.00
|
| Cost of Revenue |
$3.57 M |
$2.98 M |
$2.40 M |
$62.11 M |
$825,000.00 |
$205,000.00 |
| Gross Profit |
$75.03 M |
$43.85 M |
$70.44 M |
-$28.07 M |
$2.11 M |
-$205,000.00 |
| Gross Profit Ratio |
0.95 |
0.94 |
0.97 |
-0.82 |
0.72 |
0 |
| Research and Development
Expenses |
$189.08 M
|
$164.25 M
|
$137.02 M
|
$62.11 M
|
$37.16 M
|
$17.68 M
|
| General & Administrative
Expenses |
$55.04 M
|
$43.83 M
|
$36.35 M
|
$18.23 M
|
$7.98 M
|
$3.77 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$55.04 M
|
$43.83 M
|
$36.35 M
|
$18.23 M
|
$7.98 M
|
$3.77 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$244.12 M |
$208.08 M |
$173.36 M |
$80.34 M |
$45.14 M |
$21.45 M |
| Cost And Expenses |
$244.12 M |
$208.08 M |
$173.36 M |
$80.34 M |
$45.14 M |
$21.45 M |
| Interest Income |
$18.76 M |
$6.62 M |
$488,000.00 |
$826,000.00 |
$1.01 M |
$0.00 |
| Interest Expense |
$196,000.00 |
$176,000.00 |
$175,000.00 |
$115,000.00 |
$46,000.00 |
$16,000.00 |
| Depreciation &
Amortization |
$3.57 M
|
$2.98 M
|
$2.40 M
|
$1.76 M
|
$825,000.00
|
$205,000.00
|
| EBITDA |
-$143.20 M
|
-$154.63 M
|
-$100.04 M
|
-$45.48 M
|
-$40.38 M
|
-$21.25 M
|
| EBITDA Ratio |
-1.82 |
-3.3 |
-1.37 |
-1.34 |
-13.76 |
0 |
| Operating Income Ratio
|
-2.11
|
-3.44
|
-1.38
|
-1.36
|
-14.38
|
0
|
| Total Other
Income/Expenses Net |
$18.57 M
|
$6.45 M
|
$313,000.00
|
$711,000.00
|
$959,000.00
|
-$16,000.00
|
| Income Before Tax |
-$146.96 M |
-$154.81 M |
-$100.22 M |
-$45.59 M |
-$41.25 M |
-$21.47 M |
| Income Before Tax Ratio
|
-1.87
|
-3.31
|
-1.38
|
-1.34
|
-14.06
|
0
|
| Income Tax Expense |
$18.76 M |
-$2.98 M |
-$2.22 M |
-$1.65 M |
$46,000.00 |
$43,859.00 |
| Net Income |
-$146.96 M |
-$151.83 M |
-$98.00 M |
-$43.95 M |
-$41.29 M |
-$21.47 M |
| Net Income Ratio |
-1.87 |
-3.24 |
-1.35 |
-1.29 |
-14.07 |
0 |
| EPS |
-2.52 |
-2.82 |
-2.04 |
-2.53 |
-0.93 |
-0.48 |
| EPS Diluted |
-2.52 |
-2.82 |
-2.04 |
-2.53 |
-0.93 |
-0.48 |
| Weighted Average Shares
Out |
$58.37 M
|
$53.93 M
|
$47.99 M
|
$17.35 M
|
$44.53 M
|
$44.53 M
|
| Weighted Average Shares
Out Diluted |
$58.37 M
|
$53.93 M
|
$47.99 M
|
$17.35 M
|
$44.53 M
|
$44.53 M
|
| Link |
|
|
|
|
|
|
